Actual Medicinal Product (AMP) Tildiem LA 300 capsules (Dowelhurst Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label. Mitigation measures may need to be considered. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
- Notes
-
Should be stored in airtight, light-resistant containers. Excessive humidity should be avoided.
- Provenance
-
This compatibility recommendation is derived from Adizem-XL 300mg capsules (Napp Pharmaceuticals Ltd), Angitil XL 300 capsules (Ethypharm UK Ltd), Tildiem LA 300, Viazem XL 300mg capsules (Thornton & Ross Ltd) and Zemtard 300 XL capsules (Galen Ltd).
- Generic
- Diltiazem
- Formulation
- Diltiazem 300mg modified-release capsules
-
Diltiazem
-
Diltiazem 300mg modified-release capsules
-
Tildiem LA 300 capsules (Dowelhurst Ltd)
-
-
Diltiazem 60mg modified-release capsules